239 related articles for article (PubMed ID: 24011291)
21. Liver transplantation for hepatocellular carcinoma: the MELD impact.
Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
[TBL] [Abstract][Full Text] [Related]
22. Impact of Median MELD at Transplant Minus 3 National Policy on Quality of Transplanted Livers for Patients With and Without Hepatocellular Carcinoma.
Mazur RD; Cron DC; Chang DC; Yeh H; Dageforde LAD
Transplantation; 2024 Jan; 108(1):204-214. PubMed ID: 37189232
[TBL] [Abstract][Full Text] [Related]
23. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
[TBL] [Abstract][Full Text] [Related]
24. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
[TBL] [Abstract][Full Text] [Related]
25. Factors that affect deceased donor liver transplantation rates in the United States in addition to the Model for End-stage Liver Disease score.
Sharma P; Schaubel DE; Messersmith EE; Guidinger MK; Merion RM
Liver Transpl; 2012 Dec; 18(12):1456-63. PubMed ID: 22965903
[TBL] [Abstract][Full Text] [Related]
26. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
Shah RH; Chyou D; Goldberg DS
Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
[TBL] [Abstract][Full Text] [Related]
27. Racial-ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy.
Mazur RD; Cron DC; Goldberg DS; Yeh H; Dageforde LA
Clin Transplant; 2024 Jun; 38(6):e15365. PubMed ID: 38804605
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
29. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
Kwong AJ; Lai JC; Dodge JL; Roberts JP
Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
[TBL] [Abstract][Full Text] [Related]
30. Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system.
Francoz C; Belghiti J; Castaing D; Chazouillères O; Duclos-Vallée JC; Duvoux C; Lerut J; Le Treut YP; Moreau R; Mandot A; Pageaux G; Samuel D; Thabut D; Valla D; Durand F
Liver Transpl; 2011 Oct; 17(10):1137-51. PubMed ID: 21695771
[TBL] [Abstract][Full Text] [Related]
31. Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma.
Kensinger CD; Feurer ID; O'Dell HW; LaNeve DC; Simmons L; Pinson CW; Moore DE
Clin Transplant; 2016 Sep; 30(9):1036-45. PubMed ID: 27291713
[TBL] [Abstract][Full Text] [Related]
32. Geographic inequity in access to livers for transplantation.
Yeh H; Smoot E; Schoenfeld DA; Markmann JF
Transplantation; 2011 Feb; 91(4):479-86. PubMed ID: 21200366
[TBL] [Abstract][Full Text] [Related]
33. Outcomes utilizing imported liver grafts for recipients with hepatocellular carcinoma.
Battula N; Reichman TW; Amiri Y; Carmody IC; Galliano G; Seal J; Bugeaud E; Bohorquez H; Bruce D; Cohen A; Loss GE
Liver Transpl; 2017 Mar; 23(3):299-304. PubMed ID: 28026108
[TBL] [Abstract][Full Text] [Related]
34. MELD as a metric for survival benefit of liver transplantation.
Luo X; Leanza J; Massie AB; Garonzik-Wang JM; Haugen CE; Gentry SE; Ottmann SE; Segev DL
Am J Transplant; 2018 May; 18(5):1231-1237. PubMed ID: 29316310
[TBL] [Abstract][Full Text] [Related]
35. Improvement in the Outcomes of MELD ≥ 40 Liver Transplantation: An Analysis of 207 Consecutive Transplants in a Highly Competitive DSA.
Nekrasov V; Matsuoka L; Kaur N; Pita A; Whang G; Cao S; Groshen S; Alexopoulos S
Transplantation; 2017 Oct; 101(10):2360-2367. PubMed ID: 28319564
[TBL] [Abstract][Full Text] [Related]
36. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
Ravaioli M; Lai Q; Sessa M; Ghinolfi D; Fallani G; Patrono D; Di Sandro S; Avolio A; Odaldi F; Bronzoni J; Tandoi F; De Carlis R; Pascale MM; Mennini G; Germinario G; Rossi M; Agnes S; De Carlis L; Cescon M; Romagnoli R; De Simone P
J Hepatol; 2022 Mar; 76(3):619-627. PubMed ID: 34774638
[TBL] [Abstract][Full Text] [Related]
37. Impact of Model for End-stage Liver Disease Score-based Allocation System in Korea: A Nationwide Study.
Lee J; Kim DG; Lee JY; Lee JG; Joo DJ; Kim SI; Kim MS
Transplantation; 2019 Dec; 103(12):2515-2522. PubMed ID: 30985735
[TBL] [Abstract][Full Text] [Related]
38. Prospective validation of a new priority allocation model for liver transplant candidates: an interim analysis.
Vitale A; Saracino E; D'Amico FE; Grigoletto F; Burra P; Angeli P; Boccagni P; Brolese A; Zanus G; Neri D; Gringeri E; D'Amico F; Valmasoni M; Carraro A; Gambato M; Feltracco P; Romano A; Buggio M; D'Amico DF; Cillo U
Transplant Proc; 2009 May; 41(4):1092-5. PubMed ID: 19460489
[TBL] [Abstract][Full Text] [Related]
39. Region 11 MELD Na exception prospective study.
Fisher RA; Heuman DM; Harper AM; Behnke MK; Smith AD; Russo MW; Zacks S; McGillicuddy JW; Eason J; Porayko MK; Northup P; Marvin MR; Hundley J; Nair S
Ann Hepatol; 2012; 11(1):62-7. PubMed ID: 22166562
[TBL] [Abstract][Full Text] [Related]
40. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy.
Wiesner RH; Freeman RB; Mulligan DC
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S261-7. PubMed ID: 15508092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
